Cargando…

NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology

Neurofibromatosis Type I (NF1) is an autosomal dominant genetic syndrome that is inherited or sporadic. Neuro-Oncology nurses are experienced in the multidisciplinary care of NF1 patients due to an increased incidence of brain tumors and the treatment of plexiform neurofibromas with Mek inhibitors....

Descripción completa

Detalles Bibliográficos
Autor principal:	Hemenway, Molly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neurofibromatosis and other Predisposition Syndromes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164982/ http://dx.doi.org/10.1093/neuonc/noac079.481

Ejemplares similares

NFB-15. "Cognitive Impairments in Children and Adolescents with Neurofibromatosis"
por: Mavrea, Kalliopi, et al.
Publicado: (2022)

NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
por: Roka, Kleoniki, et al.
Publicado: (2022)

NFB-03. Neurological manifestations in children and adolescents with Neurofibromatosis type 1 - Implications for management and surveillance
por: Angelova-Toshkina, Daniela, et al.
Publicado: (2022)

NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
por: Kiaei, Dorsa Sadat, et al.
Publicado: (2022)

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B
por: Pillay Smiley, Natasha, et al.
Publicado: (2022)

NFB-07. Meningiomatosis in an adolescent with TRAF-7 mutation related syndrome
por: Torres, Marleni, et al.
Publicado: (2022)

NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas
por: Putnam, Ethan, et al.
Publicado: (2022)

NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
por: Marks, Asher, et al.
Publicado: (2022)

NFB-09. Treatment of cardiac fibroma in aPTCH1-mutated Gorlin syndrome with medulloblastoma
por: Piccolo, Gianluca, et al.
Publicado: (2022)

NFB-06. Laser Interstitial Thermal Therapy as a Radiation-Sparing Approach for Children with Cancer Predisposition
por: Guadix, Sergio, et al.
Publicado: (2022)

NFB-12. Effect of trametinib on leg length discrepancy in a child with NF1 related plexiform neurofibroma
por: Pradeep, Celia, et al.
Publicado: (2022)

NFB-23. Extent of tumor but not location may be predictive of longitudinal disease severity in children with NF1-associated gliomas requiring treatment
por: Chaturvedi, Sneha, et al.
Publicado: (2022)

NFB-02. Maternal high-fat diet exposure increases the proliferation and glial differentiation of the cells of origin for NF1-optic glioma
por: Zhang, Kailong, et al.
Publicado: (2022)

NFB-01. Central nervous system tumors in Von Hippel-Lindau multisystem disorder: are there preventive approaches to escape tumor initiation at a young age?
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2022)

NFB-02. TREATMENT OF PAIN AND TUMOR GROWTH IN NF2
por: Hemenway, Molly, et al.
Publicado: (2020)

NFB-14. PSYCHOSOCIAL OUTCOMES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS
por: Damodharan, Sudarshawn, et al.
Publicado: (2020)

NFB-05. AN UNUSUAL PRESENTATION OF RECURRENT LANGERHANS CELL HISTIOCYTOSIS OF THE CRANIOFACIAL BONES IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
por: Chaffee, Blake, et al.
Publicado: (2020)

NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020)

NFB-04. EXAMINING DIFFUSION, ARTERIAL SPIN-LABELED PERFUSION, AND VOLUMETRIC CHANGES IN THE NEUROFIBROMATOSIS TYPE 1 BRAIN USING AN ATLAS-BASED, MULTI-PARAMETRIC APPROACH
por: Tam, Lydia, et al.
Publicado: (2020)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
por: Mueller, Sabine, et al.
Publicado: (2020)

NFB-13. TRAMETINIB FOR PLEXIFORM NEUROFIBROMA AND RECURRENT LOW-GRADE GLIOMA
por: Sato, Aimee, et al.
Publicado: (2020)

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
por: Fisher, Michael J, et al.
Publicado: (2020)

NFB-03. TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1
por: Toledano, Helen, et al.
Publicado: (2020)

NFB-11. WHITE MATTER DIFFERENCES IN CHILDREN WITH NF1 COMPARED TO CONTROLS
por: Bruckert, Lisa, et al.
Publicado: (2020)

NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST
por: Yuan, Ming, et al.
Publicado: (2020)

NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA
por: Hounjet, Celine D, et al.
Publicado: (2020)

NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE
por: Cacchione, Antonella, et al.
Publicado: (2020)

NFB-16. mTOROPATHIES AND SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: PREDICTIVE VALUE OF GERMINAL TSC1/2 MUTATIONS SCREENING IN FAMILIAL CASES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2020)

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
por: Baig, Muhammed, et al.
Publicado: (2020)

MRI Screening for Optic Gliomas in Neurofibromatosis Type 1
por: Millichap, J. Gordon
Publicado: (2015)

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
por: Hillen, Maarten R, et al.
Publicado: (2020)

Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero
por: Hedlund, Malin, et al.
Publicado: (2020)

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response
por: Hamkour, Safae, et al.
Publicado: (2023)

Predictive Power of EEG in Infants with Tuberous Sclerosis
por: Tracy, Molly
Publicado: (2016)

Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma
por: Pontarini, Elena, et al.
Publicado: (2020)

Do you know this syndrome? Type 2 benign symmetric lipomatosis (Launois-Bensaude)
por: Esposito, Ana Cláudia Cavalcante, et al.
Publicado: (2016)

Salivary Gland Mucosa‐Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity‐Selected for IgG
por: Bende, Richard J., et al.
Publicado: (2020)

RARE-04. IMPACT OF LIVE, VIRTUAL EDUCATIONAL SYMPOSIA ON PEDIATRIC NEURO-ONCOLOGIST, NEURO-ONCOLOGIST, AND NEUROSURGEON CONFIDENCE, KNOWLEDGE, AND INTENTION TO EMPLOY TARGETED MEDICAL THERAPIES FOR THEIR PATIENTS WITH NEUROFIBROMATOSIS TYPE 1
por: Taylor, Bryan, et al.
Publicado: (2021)

OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO)
por: Malbari, Fatema, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ccodftjbshq70bi0hu5p311ca7